"The most effective way to stop the global TB epidemic is to prevent the spread of M. tuberculosis, but that is becoming increasingly difficult with the rise of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), the latter of which is resistant to most first- and second-line drugs.
Aeras was founded in 1997 to develop new concepts and tools to control the global TB epidemic. It is the goal of Aeras to develop, test, characterize, license, manufacture and distribute at least one new TB vaccine within 10 years.
GSK has long been committed to developing an effective tool against TB disease. For about 10 years, the company has been working with organizations such as Aeras in the development of a TB vaccine to ensure access to an effective TB vaccine to the populations who need it most. GSK’s current M72/AS01E candidate prophylactic vaccine has been tested in early stage Phase I/II studies in Europe and TB endemic countries. In October 2012, GSK and Aeras entered into a new agreement with the goal of assessing the potential efficacy of the M72/AS01E candidate vaccine against TB disease and to investigate biomarkers of risk for TB disease and possible correlates of protection, which would benefit the TB vaccine field in general. The trial is targeted to start in summer 2014 and will enrol more than 3500 participants across several trial sites in South Africa, Zambia and Kenya."
|Location||Eastern Europe, West Africa, Central Africa, Central Asia, East Asia and Pacific, Eastern Africa, Latin America and Caribbean, North Africa and Middle East, South Asia, Southern Africa|